Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2013Cited by 49 (Europe PMC)

PMID22836585DOI10.1002/jbmr.1716PepBankPUB-22836585

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, P1NP did not change during continued teriparatide monotherapy.
In plain wordsIn women with severe osteoporosis, P1NP did not change during continued teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeP1NP during monotherapy
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 9 monthsAs given in this study (human).
Measurements
P1NP concentration
693%
TPTD monotherapy
Source sentences
Summary
During the combination period, P1NP concentrations did not change on TPTD monotherapy (693% ± 371%, p < 0.0001) and decreased in the ALN (360% ± 153%, p < 0.0001) and RAL (482% ± 243%, p < 0.0001) combination groups;
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
Report a problemFND-2283658501
02HumanRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, CTX did not change during continued teriparatide monotherapy.
In plain wordsIn women with severe osteoporosis, CTX did not change during continued teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCTX during monotherapy
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 9 monthsAs given in this study (human).
Measurements
CTX
283%
teriparatide monotherapy group, reported as 283% ± 215%, p < 0.0001
Source sentences
Summary
whereas CTX did not change on TPTD monotherapy (283% ± 215%, p < 0.0001), decreased to the starting level in the ALN combination group (17% ± 72%, p = 0.39), and remained elevated in the RAL combination group (179% ± 341%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
Report a problemFND-2283658504

Studies that did not test the peptide alone13

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, P1NP decreased during alendronate plus teriparatide treatment.
In plain wordsIn women with severe osteoporosis, P1NP decreased during alendronate plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseP1NP with alendronate combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
P1NP concentration
360%
alendronate plus teriparatide
Source sentences
Summary
During the combination period, P1NP concentrations did not change on TPTD monotherapy (693% ± 371%, p < 0.0001) and decreased in the ALN (360% ± 153%, p < 0.0001) and RAL (482% ± 243%, p < 0.0001) combination groups;
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658502
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, P1NP decreased during raloxifene plus teriparatide treatment.
In plain wordsIn women with severe osteoporosis, P1NP decreased during raloxifene plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseP1NP with raloxifene combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
P1NP concentration
482%
raloxifene plus teriparatide
Source sentences
Summary
During the combination period, P1NP concentrations did not change on TPTD monotherapy (693% ± 371%, p < 0.0001) and decreased in the ALN (360% ± 153%, p < 0.0001) and RAL (482% ± 243%, p < 0.0001) combination groups;
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658503
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, CTX decreased to its starting level during alendronate plus teriparatide treatment.
In plain wordsIn women with severe osteoporosis, CTX returned to its starting level during alendronate plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCTX with alendronate combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
CTX
17%
alendronate plus teriparatide group, reported as 17% ± 72%, p = 0.39
Source sentences
Summary
whereas CTX did not change on TPTD monotherapy (283% ± 215%, p < 0.0001), decreased to the starting level in the ALN combination group (17% ± 72%, p = 0.39), and remained elevated in the RAL combination group (179% ± 341%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658505
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, CTX remained elevated during raloxifene plus teriparatide treatment.
In plain wordsIn women with severe osteoporosis, CTX remained elevated during raloxifene plus teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedCTX with raloxifene combination
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
CTX
179%
raloxifene plus teriparatide group, reported as 179% ± 341%, p < 0.0001
Source sentences
Summary
whereas CTX did not change on TPTD monotherapy (283% ± 215%, p < 0.0001), decreased to the starting level in the ALN combination group (17% ± 72%, p = 0.39), and remained elevated in the RAL combination group (179% ± 341%, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658506
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, lumbar BMD gains did not differ significantly between alendronate plus teriparatide and teriparatide alone.
In plain wordsIn women with osteoporosis, spine bone density gains did not differ significantly between alendronate plus teriparatide and teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD with alendronate
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
5%
alendronate plus teriparatide group, reported as 5% ± 6.3%
Lumbar spine BMD increase
2.8%
teriparatide monotherapy group, reported as 2.8% ± 9.3%
Source sentences
Summary
The increase in lumbar spine BMD was 5% ± 6.3% in the ALN and 6% ± 5.2% in the RAL combination groups compared with 2.8% ± 9.3% in the TPTD monotherapy group (p = 0.085 and p = 0.033, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658507
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, raloxifene plus teriparatide increased lumbar BMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, raloxifene plus teriparatide increased spine bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with raloxifene
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
6%
raloxifene plus teriparatide group, reported as 6% ± 5.2%
Lumbar spine BMD increase
2.8%
teriparatide monotherapy group, reported as 2.8% ± 9.3%
Source sentences
Summary
The increase in lumbar spine BMD was 5% ± 6.3% in the ALN and 6% ± 5.2% in the RAL combination groups compared with 2.8% ± 9.3% in the TPTD monotherapy group (p = 0.085 and p = 0.033, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658508
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, alendronate plus teriparatide increased trabecular lumbar BMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, alendronate plus teriparatide increased trabecular spine density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular lumbar BMD with alendronate
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The increase of trabecular lumbar spine BMD for both the ALN and RAL combination groups was superior to TPTD monotherapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658509
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, raloxifene plus teriparatide increased trabecular lumbar BMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, raloxifene plus teriparatide increased trabecular spine density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular lumbar BMD with raloxifene
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The increase of trabecular lumbar spine BMD for both the ALN and RAL combination groups was superior to TPTD monotherapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658510
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, alendronate plus teriparatide increased total hip BMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, alendronate plus teriparatide increased hip bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD with alendronate
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
4%
alendronate plus teriparatide group, reported as 4% ± 5.3%
Total hip BMD change
1.4%
teriparatide monotherapy group, reported as 1.4% ± 5.1%
Source sentences
Summary
Total hip BMD changes were 4% ± 5.3% for the ALN combination group and 1.4% ± 5.1% for the TPTD monotherapy (p = 0.032), and 1.4% ± 3.4% (p = 0.02) for the RAL combination group.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658511
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with severe osteoporosis, total hip BMD change was 1.4% ± 3.4% (p = 0.02) in the raloxifene plus teriparatide group.
In plain wordsIn women with osteoporosis, hip bone density changed by 1.4% in the raloxifene plus teriparatide group.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedTotal hip BMD with raloxifene
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
1.4%
raloxifene plus teriparatide group, reported as 1.4% ± 3.4%, p = 0.02
Source sentences
Summary
Total hip BMD changes were 4% ± 5.3% for the ALN combination group and 1.4% ± 5.1% for the TPTD monotherapy (p = 0.032), and 1.4% ± 3.4% (p = 0.02) for the RAL combination group.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658512
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck trabecular volumetric BMD did not differ between the alendronate combination and other groups.
In plain wordsIn women with osteoporosis, femoral neck trabecular density did not differ between the alendronate combination and other groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck trabecular volumetric BMD
Study
n: not reported in source
Comparator
Raloxifene combination and teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With the exception of no differences in the trabecular compartment of femoral neck, volumetric BMD changes in the ALN combination group for all other comparisons were significantly superior to the two other groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658513
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, other volumetric BMD changes favored alendronate plus teriparatide over raloxifene plus teriparatide.
In plain wordsIn women with osteoporosis, other volumetric bone density changes favored alendronate plus teriparatide over raloxifene plus teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOther volumetric BMD comparisons
Study
n: not reported in source
Comparator
Raloxifene plus teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With the exception of no differences in the trabecular compartment of femoral neck, volumetric BMD changes in the ALN combination group for all other comparisons were significantly superior to the two other groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658514
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, other volumetric BMD changes favored alendronate plus teriparatide over teriparatide alone.
In plain wordsIn women with osteoporosis, other volumetric bone density changes favored alendronate plus teriparatide over teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOther volumetric BMD comparisons
Study
n: not reported in source
Comparator
Teriparatide monotherapy
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With the exception of no differences in the trabecular compartment of femoral neck, volumetric BMD changes in the ALN combination group for all other comparisons were significantly superior to the two other groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women (n = 125) with severe osteoporosis on TPTD treatment for 9 months were randomized into three open-label groups for a further 9 months: ALN (70 mg/week) in addition to TPTD; RAL (60 mg/d) in addition to TPTD; or no medication in addition to TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2283658515

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.